A Phase II/III of Hepenofovir Fumarate Tablets (HTS) for Chronic Hepatitis B
Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2030-02-28
Target enrollment:
Participant gender:
Summary
UsingTAF as the control, the nvestigators aim to further explore the efficacy and safety of different dosages of HTS in the treatment of patients with chronic hepatitis B; ultimately, the nvestigators determine the optimal recommended dosage of HTS to provide a basis for Phase III confirmatory clinical research.